Recent comprehensive reviews outline the pathogenic role of Fusobacterium nucleatum in colorectal cancer, including its influence on tumor initiation, progression, metastasis and resistance to conventional therapies. Therapeutic strategies targeting Fn include small molecules, nanomedicines, and biopharmaceuticals, although challenges remain in achieving specificity and safety. Continued research aims to develop precision interventions to counteract Fn's tumorigenic effects and improve patient outcomes through microbiome modulation.